Abstract
Although an increased oxidative stress has been associated with several pathologies, predictive value of circulating oxidative stress biomarkers remains poorly understood. It has been demonstrated that several pathologies underestimated in women, including cardiovascular diseases, develop differently by gender. In this study, conducted on 195 healthy volunteers, we assessed the putative gender difference in prooxidant and antioxidant status. Our results were successful in demonstrating a significant difference in oxidative stress between sexes, whereas no difference was found in the plasma antioxidant barrier efficiency. To assess whether this difference was due to hormonal status (i.e. estrogen levels), female samples were divided into pre-menopausal and post-menopausal groups. No significant difference emerged for both biomarkers. Despite the well-known antioxidant estrogen role, women in this study presented a higher oxidative status than males. This suggests that there is a difference in the production and metabolic deactivation of reactive oxygen metabolite.
Keywords: Antioxidant capacity, gender differences, healthy subject, oxidative stress, predictive biomarkers, reactive oxygen species.
Current Drug Targets
Title:Sex Differences in Oxidative Stress Biomarkers
Volume: 15 Issue: 8
Author(s): Elvira Brunelli, Francesco Domanico, Daniele La Russa and Daniela Pellegrino
Affiliation:
Keywords: Antioxidant capacity, gender differences, healthy subject, oxidative stress, predictive biomarkers, reactive oxygen species.
Abstract: Although an increased oxidative stress has been associated with several pathologies, predictive value of circulating oxidative stress biomarkers remains poorly understood. It has been demonstrated that several pathologies underestimated in women, including cardiovascular diseases, develop differently by gender. In this study, conducted on 195 healthy volunteers, we assessed the putative gender difference in prooxidant and antioxidant status. Our results were successful in demonstrating a significant difference in oxidative stress between sexes, whereas no difference was found in the plasma antioxidant barrier efficiency. To assess whether this difference was due to hormonal status (i.e. estrogen levels), female samples were divided into pre-menopausal and post-menopausal groups. No significant difference emerged for both biomarkers. Despite the well-known antioxidant estrogen role, women in this study presented a higher oxidative status than males. This suggests that there is a difference in the production and metabolic deactivation of reactive oxygen metabolite.
Export Options
About this article
Cite this article as:
Brunelli Elvira, Domanico Francesco, Russa La Daniele and Pellegrino Daniela, Sex Differences in Oxidative Stress Biomarkers, Current Drug Targets 2014; 15 (8) . https://dx.doi.org/10.2174/1389450115666140624112317
DOI https://dx.doi.org/10.2174/1389450115666140624112317 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Use of Insulin and Insulin Analogs and Risk of Cancer — Systematic Review and Meta-Analysis of Observational Studies
Current Drug Safety Non-Peptidic Small-Molecule Antagonists of the Human Platelet Thrombin Receptor PAR-1
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Members of CRF Family and their Receptors: From Past to Future
Current Medicinal Chemistry Hyperhomocysteinemia and Endothelial Dysfunction
Current Hypertension Reviews Mechanisms of the Penetration of Blood-Borne Substances into the Brain
Current Neuropharmacology Preface
Current Pharmaceutical Design Is the Use of Autologous Platelet-Rich Plasma Gels in Gynecologic, Cardiac, and General, Reconstructive Surgery Beneficial?
Current Pharmaceutical Biotechnology Biology and Pharmacology of the Platelet P2Y12 Receptor
Current Pharmaceutical Design Modafinil: A Useful Medication for Cocaine Addiction? Review of the Evidence from Neuropharmacological, Experimental and Clinical Studies
Current Drug Abuse Reviews The Role of the Methoxyphenol Apocynin, a Vascular NADPH Oxidase Inhibitor, as a Chemopreventative Agent in the Potential Treatment of Cardiovascular Diseases
Current Vascular Pharmacology Mechanisms of Cardiovascular Changes in an Experimental Model of Syndrome X and Pharmacological Intervention on the Renin-Angiotensin- System
Current Vascular Pharmacology P2X7 Receptor-Associated Programmed Cell Death in the Pathophysiology of Hemorrhagic Stroke
Current Neuropharmacology Mevalonate Cascade and Neurodevelopmental and Neurodegenerative Diseases: Future Targets for Therapeutic Application
Current Molecular Pharmacology BHUx: A Patented Polyherbal Formulation to Prevent Hyperlipidemia and Atherosclerosis
Recent Patents on Inflammation & Allergy Drug Discovery Omentin: Linking Metabolic Syndrome and Cardiovascular Disease
Current Vascular Pharmacology The Effect of Antihypertensive Agents on Insulin Sensitivity, Lipids and Haemostasis
Current Vascular Pharmacology How Effective are the Lipid Modifying Medicines at Preventing Coronary Heart Disease in Patients with the Metabolic Syndrome?
Vascular Disease Prevention (Discontinued) Nuclear Translocation of Heme Oxygenase-1 Confers Resistance to Imatinib in Chronic Myeloid Leukemia Cells
Current Pharmaceutical Design T Lymphocytes as Targets of Statins: Molecular Mechanisms and Therapeutic Perspectives
Inflammation & Allergy - Drug Targets (Discontinued) Systemic Sclerosis-Related Interstitial Lung Disease
Current Respiratory Medicine Reviews